NO20014127D0 - 5-HT1F agonister - Google Patents

5-HT1F agonister

Info

Publication number
NO20014127D0
NO20014127D0 NO20014127A NO20014127A NO20014127D0 NO 20014127 D0 NO20014127 D0 NO 20014127D0 NO 20014127 A NO20014127 A NO 20014127A NO 20014127 A NO20014127 A NO 20014127A NO 20014127 D0 NO20014127 D0 NO 20014127D0
Authority
NO
Norway
Prior art keywords
ht1f agonists
ht1f
agonists
Prior art date
Application number
NO20014127A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014127L (no
Inventor
Sandra Ann Filla
Brian Michael Mathes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20014127L publication Critical patent/NO20014127L/no
Publication of NO20014127D0 publication Critical patent/NO20014127D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20014127A 1999-02-26 2001-08-24 5-HT1F agonister NO20014127D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26
PCT/US2000/002505 WO2000050426A2 (en) 1999-02-26 2000-02-11 Furo[3, 2-b]pyridines as 5-ht1f agonists

Publications (2)

Publication Number Publication Date
NO20014127L NO20014127L (no) 2001-08-24
NO20014127D0 true NO20014127D0 (no) 2001-08-24

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014127A NO20014127D0 (no) 1999-02-26 2001-08-24 5-HT1F agonister

Country Status (21)

Country Link
EP (1) EP1155020B1 (de)
JP (1) JP2002537398A (de)
KR (1) KR20010102355A (de)
AR (1) AR026856A1 (de)
AT (1) ATE258935T1 (de)
AU (1) AU3354000A (de)
BR (1) BR0008479A (de)
CA (1) CA2371784A1 (de)
CO (1) CO5150234A1 (de)
DE (1) DE60008073T2 (de)
EA (1) EA200100918A1 (de)
ES (1) ES2214256T3 (de)
HU (1) HUP0200245A2 (de)
ID (1) ID30056A (de)
IL (1) IL144355A0 (de)
NO (1) NO20014127D0 (de)
PE (1) PE20001432A1 (de)
PL (1) PL350864A1 (de)
TR (1) TR200102436T2 (de)
WO (1) WO2000050426A2 (de)
ZA (1) ZA200106109B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
WO2005061439A1 (en) 2003-12-17 2005-07-07 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (de) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridinen als Inhibitoren von Proteinkinasen
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502816A (ja) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー 5−置換−3−(1,2,3,6−テトラヒドロピリジン−4−イル)−および3−(ピペリジン−4−イル)−1h−インドール類:新規5−ht▲下1f▼アゴニスト
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
HUP0200245A2 (en) 2002-06-29
EA200100918A1 (ru) 2002-02-28
TR200102436T2 (tr) 2002-06-21
CA2371784A1 (en) 2000-08-31
ID30056A (id) 2001-11-01
IL144355A0 (en) 2002-05-23
NO20014127L (no) 2001-08-24
ES2214256T3 (es) 2004-09-16
EP1155020A2 (de) 2001-11-21
PL350864A1 (en) 2003-02-10
ATE258935T1 (de) 2004-02-15
CO5150234A1 (es) 2002-04-29
KR20010102355A (ko) 2001-11-15
AU3354000A (en) 2000-09-14
ZA200106109B (en) 2002-07-25
WO2000050426A2 (en) 2000-08-31
DE60008073D1 (de) 2004-03-11
PE20001432A1 (es) 2000-12-18
JP2002537398A (ja) 2002-11-05
DE60008073T2 (de) 2004-08-05
AR026856A1 (es) 2003-03-05
WO2000050426A3 (en) 2000-12-21
BR0008479A (pt) 2002-01-29
EP1155020B1 (de) 2004-02-04

Similar Documents

Publication Publication Date Title
DE69929895D1 (de) Prüfvorrichtung
NO20025115L (no) Muskarin agonister
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE50002834D1 (de) Handstempel
DE60020036D1 (de) Ausgleichswellegehause
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO990431D0 (no) Golfk°llehode
DE50000805D1 (de) Aufsitzspanner
NO20014127D0 (no) 5-HT1F agonister
DE60030066D1 (de) Prüfgerät
NO20022927L (no) Substituerte pyrrazoler
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE60018655D1 (de) Prüfvorrichtung
DE10082008D2 (de) Ausbeulgerät
DE50003921D1 (de) Substituierte phenyluracile
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
DE50002156D1 (de) Azofarbstoffmischungen
DE10085167T1 (de) Gangumschalteinrichtung
ID27139A (id) Bertukol kusmargono
DE29900278U1 (de) Biobeton

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application